Open Access Articles- Top Results for Quinupramine


Systematic (IUPAC) name
Clinical data
  • (Prescription only)
Pharmacokinetic data
Half-life 33 hours
PubChem CID 93154
ChemSpider 84098
UNII 29O61HFF4L 7pxY
KEGG D07336
Chemical data
Formula C21H24N2
304.43 g/mol

Quinupramine (Kevopril, Kinupril, Adeprim, Quinuprine) is a tricyclic antidepressant (TCA) used in Europe for the treatment of depression.[1][2]

Pharmacologically, quinupramine acts in vitro as a strong muscarinic acetylcholine receptor antagonist (anticholinergic) and H1 receptor antagonist (antihistamine), moderate 5-HT2 receptor antagonist, and weak serotonin and norepinephrine reuptake inhibitor.[3] It has negligible affinity for the α1-adrenergic, α2-adrenergic, β-adrenergic, or D2 receptor.[3]

Clinically, quinupramine is reported to be stimulating similarly to imipramine, desipramine, and demexiptiline.[4] It can be inferred that its in vivo metabolites may have stronger effects on the reuptake of norepinephrine and/or serotonin than quinupramine itself.[citation needed]


  1. ^ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 908. ISBN 3-88763-075-0. 
  2. ^ José Miguel Vela; Helmut Buschmann; Jörg Holenz; Antonio Párraga; Antoni Torrens (2007). Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application. Weinheim: Wiley-VCH. p. 248. ISBN 3-527-31058-4. 
  3. ^ a b Sakamoto H, Yokoyama N, Kohno S, Ohata K (December 1984). "Receptor binding profile of quinupramine, a new tricyclic antidepressant". Japanese Journal of Pharmacology 36 (4): 455–60. PMID 6098759. doi:10.1254/jjp.36.455. 
  4. ^ Kent, Angela; M. Billiard (2003). Sleep: physiology, investigations, and medicine. New York: Kluwer Academic/Plenum. p. 233. ISBN 0-306-47406-9. 

Template:Navbox with collapsible sections

Lua error in package.lua at line 80: module 'Module:Buffer' not found.